IN THE CLAIMS

WHAT IS CLAIMED IS:

1. (CURRENTLY AMENDED) A compound of the formula:


$$\begin{pmatrix}
0 \\
\parallel \\
0
\end{pmatrix}
g$$


$$\downarrow N$$


and the pharmaceutically acceptable salts and solvates thereof, wherein:


A is selected from the group consisting of:

(1)









wherein the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of: R^9 groups, provided that when R^9 is R^{13} then R^{13} is not H;

(3)

wherein one or both of the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of: R^9 groups, provided that when R^9 is R^{13} then R^{13} is not H;

wherein the above phenyl rings of said A groups are substituted with 1 to 3 substituents each independently selected from the group consisting of: R^9 groups, provided that when R^9 is R^{13} then R^{13} is not H; and

B is selected from the group consisting of

$$R^4$$
 R^5
 R^6
 R^4
 R^5
 R^6
 R^4
 R^5
 R^6
 R^4
 R^6
 R^6
 R^4
 R^6
 R^6

$$R^{12}$$
 R^{3}
 R^{2}
 R^{3}
 R^{4}
 R^{3}
 R^{4}
 R^{3}
 R^{4}
 R^{5}
 R^{4}
 R^{5}
 $R^{$

p is 1 to 5; X is O, NH, or S; Z is 1 to 3;

 R^2 is selected from the group consisting of: hydrogen, OH, -C(O)OH, -SH, -SO_2NR^{13}R^{14}, -NHC(O)R^{13}, -NHSO_2NR^{13}R^{14}, -NHSO_2R^{13}, -NR^{13}R^{14}, -C(O)NR^{13}R^{14}, -C(O)NHOR^{13}, -C(O)NR^{13}OH, -S(O_2)OH, -OC(O)R^{13}, an unsubstituted heterocyclic acidic functional group, and a substituted heterocyclic acidic functional group; wherein there are 1 to 6 substituents on said substituted heterocyclic acidic functional group each substituent being independently selected from the group consisting of: R^9

groups, and wherein the heterocyclic acidic functional group is selected from the group consisting of pyrrole, imidazole, triazole, and tetrazole;

each R³ and R⁴ is independently selected from the group consisting of: hydrogen, cyano, halogen, alkyl, alkoxy, cycloalkyl substituted with 1 to 4 alkyl groups wherein each alkyl group is independently selected, unsubstituted cycloalkyl, cycloalkyl substituted with 1 to 4 alkyl groups, -OH, -CF₃, -OCF₃, -NO₂, -C(O)R¹³, -C(O)OR¹³, -C(O)NHR¹¬, -C(O)NR¹¬R¹⁴, -SO(t)NR¹¬R¹⁴, -SO(t)R¹¬, -C(O)NR¹¬, -C(O)NR¹¬, unsubstituted or substituted heteroaryl,

$$\begin{cases} R^{31} & R^{13} \\ P - R^{31} & R^{14} \\ N & R^{30} \\ N & R^{30} \end{cases}$$
 and
$$\begin{cases} R^{14} & R^{13} \\ R^{14} & R^{14} \\ R^{15} & R^{14} \\ R^{15} & R^{14} \\ R^{15} & R^{15} \\ R^{15$$

wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of: R⁹ groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of: R⁹ groups; or

R³ is and R⁴ taken together with the carbons atoms to which they are bonded to in the the phenyl B substituent

form a fused ring of the formula:

$$R^{13}-N \xrightarrow{Z^1} R^6 \qquad \text{or} \qquad R^{13} \xrightarrow{R^2} R^6$$

wherein Z^1 or Z^2 is an unsubstituted or substituted saturated heterocyclic ring (preferably a 4 to 7 membered heterocyclic ring), said ring Z^1 or Z^2 optionally containing one additional heteroatom selected from the group consisting of: O, S and NR¹⁸; wherein there are 1 to 3 substituents on said ring Z^1 or Z^2 , and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkyl, cycloalkyl,

heteroaryl, heteroarylalkyl, amino, -C(O)OR¹⁵, -C(O)NR¹⁵R¹⁶, -SO_tNR¹⁵R¹⁶, -C(O)R¹⁵, -SO₂R¹⁵ provided that R¹⁵ is not H, -NHC(O)NR¹⁵R¹⁶, -NHC(O)OR¹⁵, halogen, and a heterocycloalkenyl group;

each R^5 and R^6 are the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, -CF₃, -OCF₃, -NO₂, -C(O)R¹³, -C(O)OR¹³, -C(O)NR¹³R¹⁴, -SO_(t)NR¹³R¹⁴, -C(O)NR¹³OR¹⁴, cyano, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of: R^9 groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of: R^9 groups;

each R⁷ and R⁸ is independently selected from the group consisting of: H, unsubstituted or substituted aryl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, -CO₂R¹³, -CONR¹³R¹⁴, alkynyl, alkenyl, and cycloalkenyl; and wherein there are one or more substituents on said substituted R⁷ and R⁸ groups, wherein each substitutent is independently selected from the group consisting of:

- a) halogen,
- b) $-CF_3$,
- c) –COR¹³,
- d) $-OR^{13}$,
- e) $-NR^{13}R^{14}$,
- f) $-NO_2$,
- g) –CN,
- h) -SO₂OR¹³,
- i) —Si(alkyl)₃, wherein each alkyl is independently selected,
- j) —Si(aryl)₃, wherein each alkyl is independently selected,
- k) $-(R^{13})_2R^{14}Si$, wherein each R^{13} is independently selected,
- I) $-CO_2R^{13}$,

- m) $-C(O)NR^{13}R^{14}$,
- n) $-SO_2NR^{13}R^{14}$,
- o) $-SO_2R^{13}$,
- p) $-OC(O)R^{13}$,
- q) $-OC(O)NR^{13}R^{14}$,
- r) $-NR^{13}C(O)R^{14}$, and
- s) $-NR^{13}CO_2R^{14}$;

(fluoroalkyl is one non-limiting example of an alkyl group that is substituted with halogen);

R^{8a} is selected from the group consisting of: hydrogen, alkyl, cycloalkyl and cycloalkylalkyl;

each R⁹ is independently selected from the group consisting of:

- a) $-R^{13}$,
- b) halogen,
- c) -CF₃,
- d) $-COR^{13}$,
- e) $-OR^{13}$,
- f) $-NR^{13}R^{14}$,
- g) $-NO_2$,
- h) -CN,
- i) -SO₂R¹³,
- j) -SO₂NR¹³R¹⁴,
- k) $-NR^{13}COR^{14}$,
- I) $-CONR^{13}R^{14}$,
- m) $-NR^{13}CO_2R^{14}$,
- n) $-CO_2R^{13}$,
- 0)

p) alkyl substituted with one or more –OH groups,

- q) alkyl substituted with one or more –NR¹³R¹⁴ group, and
- r) $-N(R^{13})SO_2R^{14}$;

each R^{10} and R^{11} is independently selected from the group consisting of R^{13} , halogen, $-CF_3$, $-OCF_3$, $-NR^{13}R^{14}$, $-NR^{13}C(O)NR^{13}R^{14}$, -OH, $-C(O)OR^{13}$, -SH, $-SO_{(t)}NR^{13}R^{14}$, $-SO_2R^{13}$, $-NHC(O)R^{13}$, $-NHSO_2NR^{13}R^{14}$, $-NHSO_2R^{13}$, $-C(O)NR^{13}R^{14}$, $-C(O)NR^{13}OR^{14}$, $-OC(O)R^{13}$ and cyano;

R¹² is selected from the group consisting of: hydrogen, -C(O)OR¹³, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, and unsubstituted or substituted heteroarylalkyl group; wherein there are 1 to 6 substituents on the substituted R¹² groups and each substituent is independently selected from the group consisting of: R⁹ groups;

each R¹³ and R¹⁴ is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein "heterocyloalkyl" means heterocyclic); wherein there are 1 to 6 substituents on said substituted R¹³ and R¹⁴ groups and each substituent is independently selected from the group consisting of: alkyl, -CF₃, -OH, alkoxy, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, -N(R⁴⁰)₂, -C(O)OR¹⁵, -C(O)NR¹⁵R¹⁶, -S(O)_tNR¹⁵R¹⁶, -C(O)R¹⁵, -SO₂R¹⁵ provided that R¹⁵ is not H, halogen, and -NHC(O)NR¹⁵R¹⁶: or

R¹³ and R¹⁴ taken together with the nitrogen they are attached to in the groups -C(O)NR¹³R¹⁴ and -SO₂NR¹³R¹⁴ form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR¹⁸; wherein there are 1 to 3 substituents on the substituted cyclized R¹³ and R¹⁴ groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, -C(O)OR¹⁵, -C(O)NR¹⁵R¹⁶, -SO_tNR¹⁵R¹⁶, -C(O)R¹⁵, -SO₂R¹⁵ provided that R¹⁵ is not H, -NHC(O)NR¹⁵R¹⁶, -NHC(O)OR¹⁵, halogen, and a heterocycloalkenyl group;

each R¹⁵ and R¹⁶ is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl;

R¹⁷ is selected from the group consisting of: -SO₂alkyl, -SO₂aryl, -SO₂cycloalkyl, and -SO₂heteroaryl;

R¹⁸ is selected from the group consisting of: H, alkyl, aryl, heteroaryl, -C(O)R¹⁹, -SO₂R¹⁹ and -C(O)NR¹⁹R²⁰;

each R¹⁹ and R²⁰ is independently selected from the group consisting of: alkyl, aryl and heteroaryl;

 R^{30} is selected from the group consisting of: alkyl, cycloalkyl, -CN, -NO₂, or -SO₂ R^{15} provided that R^{15} is not H;

each R³¹ is independently selected from the group consisting of: unsubstituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl and unsubstituted or substituted cycloalkyl; wherein there are 1 to 6 substituents on said substituted R³¹ groups and each substituent is independently selected from the group consisting of: alkyl, halogen and -CF₃;


each R⁴⁰ is independently selected from the group consisting of: H, alkyl and cycloalkyl;

g is 1 or 2; and t is 0, 1 or 2.


- 2. (CURRENTLY AMENDED) The compound of claim 1 wherein A is selected from the group consisting of:
 - (1) unsubstituted or substituted:

$$R^7$$
 R^8 R_7 R_8 R_7 R_8 and R_7 R_8 ; and

(2) substituted:




3. (ORIGINAL) The compound of Claim 1 wherein substituent A is:




wherein the furan ring is unsubstituted or substituted with 1 or 2 alkyl groups wherein each alkyl group is independently selected, R^7 is selected from the group consisting of: -CF₃, alkyl and cycloalkyl, and R^8 is H.

4. (ORIGINAL) The compound of Claim 1 wherein substituent A is:



wherein the furan ring is substituted with 1 or 2 alkyl groups independently selected from the group consisting of methyl, ethyl and isopropyl, R⁷ is selected from the group consisting of: ethyl, isopropyl and t-butyl, and R⁸ is H.

5. (CURRENTLY AMENDED) The compound of Claim 1 wherein A is selected from the group consisting of:



6. (ORIGINAL) The compound of claim 1 wherein A is selected from the group consisting of:

7. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:

8. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:

9. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:

10. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:

11. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:

12. (ORIGINAL) The compound of Claim 1 wherein B is

13. (ORIGINAL) The compound of Claim 1 wherein B is:

wherein R² is -OH.

14. (ORIGINAL) The compound of Claim 1 wherein B is:

wherein R² is-OH, and R¹³ and R¹⁴ are independently selected from the group consisting of H and alkyl.

15. (ORIGINAL) The compound of Claim 1 wherein B is

- 16. (ORIGINAL) The compound of Claim 15 wherein R¹¹ is H.
- 17. (ORIGINAL) The compound of Claim 16 wherein R² is -OH.
- 18. (ORIGINAL) The compound of Claim 17 wherein R³ is -C(O)NR¹³R¹⁴.
- 19. (ORIGINAL) The compound of Claim 17 wherein R³ is -S(O)_tNR¹³R¹⁴.
- 20. (ORIGINAL) The compound of Claim 1 wherein B is:

wherein R² is –OH, R³ is –C(O)NR¹³R¹⁴, R¹¹ is H or methyl, and R¹³ and R¹⁴ are independently selected from the group consisting of: H, alkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heteroaryl.

21. (ORIGINAL) The compound of Claim 1 wherein B is:

$$\mathbb{R}^{3}$$
 \mathbb{R}^{2}

wherein R^2 is -OH, R^3 is $-S(O)_tNR^{13}R^{14}$, R^{11} is H or methyl, and R^{13} and R^{14} are independently selected from the group consisting of H, alkyl, unsubstituted cycloalkyl and substituted cycloalkyl.

22. (ORIGINAL) The compound of Claim 1 wherein B is:

- 23. (ORIGINAL) The compound of Claim 22 in R¹¹ is H.
- 24. (ORIGINAL) The compound of Claim 23 wherein R² is -OH.
- 25. (ORIGINAL) The compound of Claim 24 wherein R³ is -C(O)NR¹³R¹⁴.
- 26. (ORIGINAL) The compound of Claim 24 wherein R³ is -S(O)_tNR¹³R¹⁴.
- 27. (ORIGINAL) The compound of Claim 1 wherein B is:

wherein R^2 is -OH, R^3 is $-C(O)NR^{13}R^{14}$, R^{11} is H, and R^{13} and R^{14} are independently selected from the group consisting of: H, alkyl, unsubstituted heteroaryl and substituted heteroaryl.

28. (ORIGINAL) The compound of Claim 1 wherein B is:

wherein R^2 is -OH, R^3 is $-S(O)_tNR^{13}R^{14}$, R^{11} is H, and R^{13} and R^{14} are independently selected from the group consisting of H and alkyl.

29. (CURRENTLY AMENDED) The compound of Claim 1 wherein:

(1) substituent A in formula IA is selected from the group consisting

of:

wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and –CF₃; R⁷ is selected from the group consisting of: H, -CF₃, -CF₂CH₃, methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R⁸ is H; and

(b)

wherein the above ring is substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and –CF₃; R⁷ is selected from the group consisting of: H, -CF₃, -CF₂CH₃, methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R⁸ is H; and

wherein R² is selected from the group consisting of: H, -CF₃, -CF₂CH₃, methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R⁸ is H; and R^{8a} is as defined in Claim 1;

(2) substituent B in formula IA is selected from the group consisting of:

$$R^{13}$$
 R^{14}
 R^{14}
 R^{14}
 R^{14}
 R^{14}
 R^{15}
 R^{15}

wherein:

R² is selected from the group consisting of: H, OH, -NHC(O)R¹³ and -NHSO₂R¹³;

 R^3 is selected from the group consisting of: $-C(O)NR^{13}R^{14}$ $-SO_2NR^{13}R^{14}$, $-NO_2$, cyano, and $-SO_2R^{13}$;

R⁴ is selected from the group consisting of: H, -NO₂, cyano, alkyl, halogen and -CF₃;

 \mbox{R}^{5} is selected from the group consisting of: H, -CF3, -NO2, halogen and cyano;

R⁶ is selected from the group consisting of: H, alkyl and -CF₃;

 R^{11} is selected from the group consisting of: H, halogen and alkyl; and each R^{13} and R^{14} is independently selected from the group consisting of: H, unsubstituted alkyl.

30. (ORIGINAL) The compound of Claim 1 wherein:

(1) substituent A in formula IA is selected from the group consisting of:

(2) substituent B in formula IA is selected from the group consisting

of:

$$R^{13}$$
 R^{4} R^{5} R^{6} R^{3} R^{11} R^{14} R^{14} R^{14} R^{2} R^{2} R^{2} R^{11} and

wherein:

R² is -OH;

R³ is selected from the group consisting of: -SO₂NR¹³R¹⁴ and -CONR¹³R¹⁴;

R⁴ is selected form the group consisting of: H, Br, -CH₃, ethyl and -CF₃;

R⁵ is selected from the group consisting of: H and cyano;

R⁶ is selected from the group consisting of: H, -CH₃ and -CF₃;

R¹¹ is H; and

 $\mbox{\ensuremath{R^{13}}}$ and $\mbox{\ensuremath{R^{14}}}$ are independently selected from the group consisting of H and methyl.

31. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:

and substituent B is selected from the group consisting of:

32. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:

and substituent B is selected from the group consisting of:

- 33. (ORIGINAL) The compound of Claim 1 wherein g is 1.
- 34. (ORIGINAL) The compound of Claim 1 wherein g is 2.

- 35. (ORIGINAL) The compound of Claim 31 wherein g is 1.
- 36. (ORIGINAL) The compound of Claim 32 wherein g is 2.
- 37. (CURRENTLY AMENDED) A <u>sodium</u>, <u>potassium</u>, <u>calcium</u>, <u>aluminum</u>, <u>gold</u>, <u>silver</u>, <u>N-methylglucamine</u>, <u>hydrochloric</u>, <u>sulfuric</u>, <u>phosphoric</u>, <u>acetic</u>, <u>citric</u>, <u>oxalic</u>, <u>malonic</u>, <u>salicylic</u>, <u>malic</u>, <u>fumaric</u>, <u>succinic</u>, <u>ascorbic</u>, <u>maleic</u>, <u>or</u> <u>methanesulfonic</u> <u>pharmaceutically acceptable</u> salt of a compound of Claim 1.
 - 38. (ORIGINAL) A sodium salt of a compound of Claim 1.
 - 39. (ORIGINAL) A calcium salt of a compound of Claim 1.
- 40. (CURRENTLY AMENDED) The \underline{A} compound of Claim 1 selected from the group consisting of:

pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates thereof.

41. (CURRENTLY AMENDED) The compound of Claim [[1]] $\underline{40}$ selected from the group consisting of:

(a14)

(a13)

$$(a15)$$

$$(a16)$$

$$(a16)$$

$$(a17)$$

$$(a18)$$

$$(a18)$$

$$(a19)$$

$$(a21)$$

$$(a21)$$

$$(a22)$$

pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates thereof.

(a52)

(a51)

42. (CURRENTLY AMENDED) The compound of Claim 4 <u>41</u> selected from the group consisting of compounds of the formula:

$$\begin{array}{c|c} & & & & & & & & & & & & & & & & \\ & & & & & & & & & & & & \\ & & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & & \\ & & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & \\ & \\ & \\ & & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ &$$

(a25)

(a26)

$$CI \longrightarrow N$$

$$H_2N \longrightarrow OH$$

$$H_2N \longrightarrow$$

the pharmaceutically acceptable salts thereof, and the pharmaceutically acceptable solvates thereof.

43. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

45. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

46. (ORIGINAL) The compound of Claim 42 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

47. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

49. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

50. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

51. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

53. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

54. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

55. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

57. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

58. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

59. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

61. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

62. (ORIGINAL) The compound of Claim 41 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

63. (ORIGINAL) The compound of Claim 41 having the formula:

64. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

65. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

66. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:

67. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:

- 68. Canceled (without prejudice).
- 69. Canceled (without prejudice).
- 70. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable carrier.
- 71. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, and at least one other agent, medicament, antibody and/or inhibitor for treating a chemokine mediated disease, in combination with a pharmaceutically acceptable carrier.
- 72. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable carrier.
- 73. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, and at least one other agent, medicament, antibody and/or inhibitor for treating a chemokine mediated disease, in combination with a pharmaceutically acceptable carrier.
 - 74. Canceled (without prejudice).

- 75. Canceled (without prejudice).
- 76. Canceled (without prejudice).
- 77. Canceled (without prejudice).
- 78. Canceled (without prejudice).
- 79. Canceled (without prejudice).
- 80. Canceled (without prejudice).
- 81. Canceled (without prejudice).
- 82. Canceled (without prejudice).
- 83. Canceled (without prejudice).
- 84. Canceled (without prejudice).
- 85. Canceled (without prejudice).
- 86. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of glatiramer acetate, glucocorticoids, methotrexate, azothioprine, mitoxantrone, chemokine inhibitors, and CB2-selective inhibitors.
- 87. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group

- 60 consisting of: methotrexate, cyclosporin, leflunimide, sulfasalazine, β-methasone, βinterferon, glatiramer acetate, prednisone, etonercept, and infliximab. 88. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof. 89. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of COX-2 inhibitors, COX inhibitors, immunosuppressives, steroids, PDE IV inhibitors, anti-TNF- α compounds, MMP inhibitors, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, and other classes of compounds indicated for the treatment of rheumatoid arthritis. 90. (ORIGINAL) A method of treating stroke and cardiac reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of thrombolitics, antiplatelet agents. antagonists, anticoagulants, and other compounds indicated for the treatment of rheumatoid arthritis. 91. (ORIGINAL) A method of treating stroke and cardiac reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of tenecteplase, TPA, alteplase, abciximab, eftiifbatide, and heparin. (ORIGINAL) A method of treating psoriasis in a patient in need of such treatment, comprising administering to said patient a thereapeutically effective

amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of immunosuppressives, steroids, and anti-TNF- α compounds.

- 93. (ORIGINAL) A method of treating COPD in a patient in need of such treatment, comprising administering to said patient a thereapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof.
 - 94. Canceled (without prejudice).
 - 95. Canceled (without prejudice).
 - 96. Canceled (without prejudice).
 - 97. Canceled (without prejudice).
 - 98. Canceled (without prejudice).
 - 99. Canceled (without prejudice).
 - 100. Canceled (without prejudice).
 - 101. Canceled (without prejudice).
 - 102. Canceled (without prejudice).
 - 103. Canceled (without prejudice).
 - 104. Canceled (without prejudice).
 - 105. Canceled (without prejudice).

- 106. Canceled (without prejudice).
- 107. Canceled (without prejudice).
- 108. Canceled (without prejudice).
- 109. Canceled (without prejudice).
- 110. Canceled (without prejudice).
- 111. Canceled (without prejudice).
- 112. (ORGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of glatiramer acetate, glucocorticoids, methotrexate, azothioprine, mitoxantrone, chemokine inhibitors, and CB2-selective inhibitors.
- 113. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of: methotrexate, cyclosporin, leflunimide, sulfasalazine, β -methasone, β -interferon, glatiramer acetate, prednisone, etonercept, and infliximab.
- 114. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof.
- 115. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically

- 117. (ORIGINAL) A method of treating stroke and cardiac reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of tenecteplase, TPA, alteplase,
- 118. (ORIGINAL) A method of treating psoriasis in a patient in need of such treatment, comprising administering to said patient a thereapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of immunosuppressives, steroids, and anti-TNF- α compounds.
- 119. (ORIGINAL) A method of treating COPD in a patient in need of such treatment, comprising administering to said patient a thereapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof.
 - 120. Canceled (without prejudice).

abciximab, eftiifbatide, and heparin.

- 121. Canceled (without prejudice).
- 122. Canceled (without prejudice).
- 123. Canceled (without prejudice).
- 124. Canceled (without prejudice).
- 125. Canceled (without prejudice).
- 126. Canceled (without prejudice)
- 127. Canceled (without prejudice)
- 128. Canceled (without prejudice).
- 129. Canceled (without prejudice).
- 130. Canceled (without prejudice)
- 131. Canceled (without prejudice)s.
- 132. (NEW) A compound selected from the group consisting of:

| Ex. | |
|-----|-----------------|
| 2 | O, O N, S, N |
| | N OH H H |
| 3 | Q, O N, S, N |
| | N OH H H |
| 4 | Q, O N, S, N |
| | N OH H H |
| 5 | 0, 0 N, S, N |
| | O OH H H |
| 6 | |
| 7 | O OH H H |
| | OH H H |
| 8 | O, O |
| | O OH H H |

| 9 | 0,0 |
|----|----------------|
| | N N N |
| | O OH H H |
| 10 | Ö ОН Н Н \Bigg |
| 10 | NS N - |
| į. | |
| | O OH H H |
| 11 | 0,0 |
| | |
| | O OH H H |
| 12 | 0,700 |
| | H Ph |
| | OH H H N Ph |
| 13 | 0,50 |
| | |
| | O OH H |
| 14 | 0,0 |
| | N N |
| | $N \sim N$ |
| | OH H H |
| 15 | 0,0 |
| | |
| | OH H N H |
| | <u> </u> |

| 16 | O, O N, S, N |
|----|---------------------|
| | NOH H H |
| 17 | |
| | N OH H H |
| 18 | ON S N N H H |
| 19 | |
| | N N CF ₃ |
| 20 | ON ON CF3 |
| 21 | ON ON CF3 |

| 22 | O N N H O N N N N N N N N N N N N N N N |
|----|---|
| 23 | |
| 24 | ON S H H OH OH |
| 25 | O Z Z H OH OH |
| 26 | |
| 27 | ON H H H |

| 28 | |
|----|----------|
| | N OH " |
| 29 | |
| | NOH H H |
| 30 | |
| | N OH H H |
| 31 | |
| | H H |
| 32 | |
| | N OH H H |
| 33 | O S N |
| | NOH H H |

| F | |
|----|------------------|
| 34 | N N N |
| | N OH N S |
| 35 | 0,0 |
| | N N N |
| | OH H H |
| 36 | 0,0 |
| | N N |
| | N OH H H |
| 37 | 0,0 |
| | N CF3 |
| | OH H H |
| 38 | O O O |
| | |
| | OH H H |
| 39 | 0, 0 0, 0 |
| | |
| | N N Ph OH H H |
| 40 | NC NS N |
| | N N Ph |
| | он н |

| | |
|----|------------------------|
| 41 | O O N N N |
| | N N Ph OH H H |
| 42 | 0,0 |
| | O S N N |
| | N N Ph |
| 43 | 0,0 |
| | HO NON |
| | OH H H |
| 44 | OH H H |
| " | N S N |
| | |
| | он н н I |
| 45 | O, O |
| | F N N |
| | OH H H |
| 46 | 0, 20 |
| | N S N |
| | N N Ph |
| 4- | |
| 47 | O O N S N |
| | |
| | NH ₂ OH H H |
| 48 | 0, 0 |
| | 0,0 S N N |
| | N N Ph |
| 49 | |
| | |
| | N N Ph |
| | он н |

| F0 | 0.0 |
|----|--------------------|
| 50 | N.S. |
| | N CF ₃ |
| | N N |
| | NC, OH H |
| 51 | 0, 0 |
| | N N CF₃ |
| | |
| | NC OH H |
| 52 | 0,0 |
| | N N |
| | N N |
| | NC OH H |
| 53 | o o |
| | N N |
| | NH N Q |
| | NC OH H |
| 54 | 0, 0 |
| | O ₂ N N |
| | NH N O |
| | ОН |
| 55 | 0,0 |
| | N N |
| | Br N N |
| | \ |
| |)N OH |
| 56 | 0,0 |
| | N N |
| | Br—NNN |
| | Br N N O |
| | ОН |
| | |

| 57 | ON NO N |
|----|--|
| 58 | Br N N H H |
| 59 | |
| 60 | |
| 61 | 0 Z H H OH OH |
| 62 | HO ₂ C OH H H |
| 63 | HO ₂ C |

| 64 | NC OH H H |
|----|---------------------------------------|
| 65 | |
| 66 | Br OH H |
| 67 | |
| 68 | O N H H OH OH |
| 69 | O O O O O O O O O O O O O O O O O O O |

| | 0.0 |
|-----|---------------------------------------|
| 70 | N.S.N |
| | |
| | N N N |
| | OH " |
| 71 | Q, O N-S [*] , N |
| | O ₂ N N N |
| | |
| | OH H H |
| 72 | |
| | |
| | O OH H H O |
| | |
| 100 | 0,,0 |
| | N S N |
| | N |
| | OH H H |
| 101 | 9,,0 |
| | N'S'N |
| | N N N N |
| | OH H H N |
| 103 | 0,0 |
| | NSN V |
| | |
| | O OH H H |
| 104 | |
| | N.S.N. |
| | O OH H H |
| 105 | |
| | |
| | \.\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ |
| | O OH H H |

| 106 | 0.0 |
|-----|--------------------|
| 106 | N.S.N |
| | N N S |
| | O OH H H |
| 107 | Q. O. |
| 107 | N.S.N. |
| | |
| | |
| 108 | 0,0 |
| | NSN V |
| | N S S |
| | O OH H H |
| 109 | |
| | |
| | N N N N S O OH H H |
| | 0 OH H H |
| 110 | |
| | N I |
| | O OH H H |
| 111 | 9,0 |
| | NSN _ |
| | N TO N |
| | O OH H H |
| 112 | |
| | N N P |
| | N N N N N |
| | |
| 113 | |
| | NS N |
| | |
| 114 | O OH H H |
| | N S N |
| | |
| | O OH H H |

| 115 | O, O N, S, N N, N, N O OH H H |
|-----|---|
| 116 | O N H H O N H |
| 117 | O S N N H |
| 118 | |
| 119 | O O O O O O O O O O O O O O O O O O O |
| 120 | O O O O O O O O O O O O O O O O O O O |
| 121 | O O O O O O O O O O O O O O O O O O O |
| 122 | ON SIN NO |

| 123 | N S N N N N N N N N N N N N N N N N N N |
|-----|---|
| 124 | ON NO N |
| 125 | ON NO N |
| 126 | H Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z |
| 127 | ON NO N |
| 128 | H Z Z O H Z Z O D C O D |
| 129 | O O O O O O O O O O O O O O O O O O O |
| 130 | 0 |

| 131 | |
|-----|--|
| | O OH H H |
| 132 | N OH OH |
| 134 | |
| 135 | |
| 136 | ON NO N |
| 137 | ON NO N |
| 138 | |
| 139 | O O O O O O O O O O O O O O O O O O O |

| 140 | ON NH CO |
|-----|---|
| 141 | NS N N N N N N N N N N N N N N N N N N |
| 142 | N.S. N. |
| 143 | NS N N N N N N N N N N N N N N N N N N |
| 144 | NS N N N N N N N N N N N N N N N N N N |
| 145 | O O O N N N N N N N N N N N N N N N N N |
| 146 | N S N N N N N N N N N N N N N N N N N N |
| 147 | NS N N N N N N N N N N N N N N N N N N |
| 148 | O O O O O O O O O O O O O O O O O O O |

| 149 | ON NO N |
|-----|--|
| 150 | O, O N, N N, N OH H |
| 151 | O O C C C C C C C C C C C C C C C C C C |
| 152 | O O O O O O O O O O O O O O O O O O O |
| 153 | S HO HO |
| 154 | N S HO HO HO |
| 155 | S N N N H |
| 156 | ON NO HO |
| 157 | N N H H |

| 158 | S N N N N N N N N N N N N N N N N N N N |
|-----|---|
| 159 | N N H H N H N H N H N H N H N H N H N H |
| 160 | |
| 161 | O N H H O CI |
| 162 | N-SOOH OH |
| 163 | N-S OH OH |
| 164 | CI N N H H |

| 165 | CI—NHHH |
|-----|--|
| 166 | CI OH OH OH |
| 167 | HO Z H |
| 168 | |
| 169 | CI———————————————————————————————————— |
| 170 | |
| 171 | Br OH OH CI |

| 172 | 0,0 |
|-----|---------------------------------------|
| | N. N |
| | Br N N N |
| | N OH |
| 173 | 0,0 N S N |
| | |
| : | Br N N OH |
| 174 | 00 |
| 1/3 | _ NSN |
| | Br N N O H H |
| | OH H H |
| 175 | 0,0 |
| | |
| | Br N N |
| | N OH |
| 176 | O O N S N |
| | |
| | \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ |
| |) ОН 0. 0 |
| 177 | H S- NSN |
| | O HO H H |
| 178 | O O O |
| | Br N N |
| | OH H H |

| 179 | O S N N N N N N N N N N N N N N N N N N |
|-----|---|
| 180 | |
| 181 | |
| 182 | ON N H H OH OH |
| 183 | ON N N N N N N N N N N N N N N N N N N |
| 184 | N N N N O CI |
| 185 | O N N N N N N N N N N N N N N N N N N N |

| 186 | N OH H H |
|-----|---|
| 187 | O Z H H O CI |
| 188 | O S N N N N N N N N N N N N N N N N N N |

| Ex. | |
|-------|--|
| 201.1 | |
| 201.2 | |
| 201.3 | O = S N N H H OH OH |
| 201.4 | OH S N N N N N N N N N N N N N N N N N N |

| 201.5 | O=S N N H H OH |
|-------|---|
| 201.6 | N H H H H H H H H H H H H H H H H H H H |
| 201.7 | H Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z |
| 201.8 | |

| 201.9 | OES N N N H H |
|-------|--|
| 202 | 0= S N N N H H OH |
| 203 | |
| 204 | |
| 205 | |
| 206 | |

| 207 | |
|-----|---|
| 208 | O = S N N N N H H OH OH |
| 209 | O=S N N H H |
| 210 | O S N N O O O O O O O O O O O O O O O O |
| 211 | 0=s N H H OH OH |
| 212 | O S N N H H O CI |

| 213 | Br N N O CI |
|-----|-------------|
| 214 | |
| 215 | |
| 216 | |
| 217 | |
| 218 | |
| 219 | |

| 220 | N-SOH OH OH |
|-----|-------------|
| 221 | |
| 222 | |
| 223 | |
| 224 | |
| 225 | |
| 226 | |

| 227 | 0 S |
|-----|---------------------------------------|
| | |
| | O S N N N O HO HO HO |
| 228 | 0 S |
| | |
| | N N N N N N N N N N N N N N N N N N N |
| 229 | |
| | |
| | O HO H H |
| 230 | |
| | N S N N |
| | O HO H H CI |
| 231 | 0 N ^S N |
| | |
| | O S N N N O H H H |
| 020 | L CI O |
| 232 | |
| | O S N N N |
| 233 | 0 |
| | N S N N |
| | об но н н |

| 234 | |
|-----|---|
| 235 | |
| 236 | |
| 237 | |
| 238 | 0 = S N N N H H OH OH |
| 239 | O S N N N H H Br |
| 240 | O = S N N N N N N N N N N N N N N N N N N |

| 241 | 0 s\ |
|-------|---|
| | N N |
| | Br N N |
| | / (OH 31 |
| 241.1 | 0 \$ |
| | CI |
| | N S OH H H |
| 241.2 | O S |
| | CI NS N |
| | N S N N N N N N N N N N N N N N N N N N |
| 241.3 | O |
| | |
| | N-S N N N |
| 241.4 | 0 |
| | |
| | N S N N N N N N N N N N N N N N N N N N |
| 242 |) = s |
| | N S N N |
| | O HO H H |
| 243 | 0 S N |
| | -N S N N |
| | O (H H / |
| 244 | 0 = s x |
| | N S N N |
| | О НО Н Н |

| 245 | O S N N H H Br |
|-----|----------------|
| 246 | |
| 248 | |
| 249 | |
| 251 | |

| 252 | |
|-----|---|
| 254 | O S N N N N N N N N N N N N N N N N N N |
| 255 | 0=0 H-Z-Z-H O=0 H-Z-Z-H |
| 256 | |
| 257 | |

| 258 | |
|-----|-------------|
| 259 | |
| 260 | OH N N H |
| 262 | OH H H OH H |
| 263 | |

| 264 | 0 |
|-----|--|
| | F ₃ C N N N N N N N N N N N N N N N N N N N |
| 265 | 0 |
| | F ₃ C N N N N N N N N N N N N N N N N N N N |
| 266 | O |
| | O S N N H |
| 267 | 0 |
| | O=S N N N H |
| 268 | O = S |
| | S N N N N N N N N N N N N N N N N N N N |
| 269 | 0 |
| | F ₃ C O S N T |

| 270 | O S N N N H |
|-----|--|
| | O OH H H |
| 271 | S O OH H |
| 272 | F ₃ C O S N D O O O O O O O O O O O O O O O O O O |
| 273 | |
| 274 | S S N N N N H |
| 275 | F ₃ C O O O O O O O O O O O O O O O O O O O |

| 276 | CI N S N E O N N N N N N N N N N N N N N N N N |
|-----|--|
| 277 | CI N S N T T T T T T T T T T T T T T T T T |
| 278 | CI N N H N H |
| 279 | CI NH |
| 280 | |

| 281 | CI N N N N N N N N N N N N N N N N N N N |
|-----|---|
| 282 | CI N S N N N N N N N N N N N N N N N N N |
| 283 | N S OH H H |
| 284 | |
| 285 | |
| 286 | O S S N S I S I S I S I S I S I S I S I S |

| 287 | |
|-----|---|
| 289 | |
| 291 | |
| 292 | |
| 293 | O H O H O H O H O H O H O H O H O H O H |
| 294 | |

| 295 | |
|-----|--------------|
| 296 | |
| 297 | |
| 298 | O=s, N I I O |
| 299 | Br N N N H |

| 300 | Br N N N N H |
|-----|---|
| 301 | F ₃ C OH N N N N N N N N N N N N N N N N N N |
| 302 | |
| 303 | F ₃ C |
| 304 | F ₃ C O N N N H |

| 305 | |
|-----|---------------------------------------|
| 306 | |
| 307 | |
| 308 | |
| 309 | |
| 310 | N N N N N N N N N N N N N N N N N N N |

| 311 | |
|-----|--|
| 312 | |
| 313 | Br N N N N N N N N N N N N N N N N N N N |
| 314 | OSS N N N H |
| 315 | S N N N N N N N N N N N N N N N N N N N |
| 316 | S N S N S N S N S N S N S N S N S N S N |

| 317 | S N S N S N S N S N S N S N S N S N S N |
|-----|---|
| 318 | |
| 319 | |
| 320 | N S OH H |
| 321 | N S O OH H H |

| 322 | O OH H H O OH H H |
|-----|---|
| 323 | |
| 324 | N.S. N.S. N.S. N.S. N.S. N.S. N.S. N.S. |
| 325 | H S N Y N Y N Y N Y N Y N Y N Y N Y N Y N |
| 326 | H S N S N S N S N S N S N S N S N S N S |

| 327 | H S N N N N N N N N N N N N N N N N N N |
|-----|---|
| 328 | |
| 329 | H-N-S-N-H-N-N-H-N-N-H-N-N-H-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N-N-N-H-N |
| 330 | O S N N N N N N N N N N N N N N N N N N |
| 331 | N S O OH H |

| 332 | N S O OH H N H |
|-----|----------------|
| 333 | |
| 334 | |
| 335 | |
| 336 | S O OH H |

| 337 | H-NS-N-H |
|-----|-----------------|
| 338 | N S OH H |
| 339 | S O O O H |
| 340 | S O OH H |
| 341 | O O O O H H N H |

| 342 | S N N N N N N N N N N N N N N N N N N N |
|-----|---|
| 343 | |
| 344 | |
| 345 | OH S H |

| 346 | OH S N N N N N N N N N N N N N N N N N N |
|-----|--|
| 347 | OH S N N N N N N N N N N N N N N N N N N |
| 348 | D=02 H D D D D D D D D D D D D D D D D D D |
| 349 | F ₃ C N N N N O O O O O O O O O O O O O O O |

| 350 | OH S N N N N N N N N N N N N N N N N N N |
|-----|--|
| 351 | |
| 352 | O=S P H H |
| 353 | O=S N N H H H OH |

| 354 | OH N N F F N N H H |
|-----|--------------------------|
| 355 | |
| 356 | |
| 357 | OH S N H H H F |

| 358 | |
|-----|--|
| 359 | O II S N N N H H H |
| 360 | |
| 361 | F ₃ C N N N N N N N N N N N N N N N N N N N |

| 362 | F ₃ C N N N N N N N N N N N N N N N N N N N |
|-----|--|
| 363 | HOW H H Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z |
| 364 | OHO OHO OHO OHO OHO OHO OHO OHO OHO OHO |
| 365 | OES N H H |

| 366 | HO NOH H |
|-----|----------|
| 367 | O H O H |
| 368 | |
| 369 | OH OH OH |

| 370 | O S N N H H N O H |
|-----|---|
| 371 | |
| 372 | 0=s H H N N N N N N N N N N N N N N N N N |
| 373 | O S N N H H S |

| 374 | F ₃ C N N N N N N N N N N N N N N N N N N N |
|-----|--|
| 375 | O=S N N OH |
| 376 | |
| 377 | |

| 378 | Br N H H |
|-----|--|
| 379 | |
| 380 | |
| 381 | OIIS N N N N N N N N N N N N N N N N N N |

| 382 | F ₃ C N N N N N N N N N N N N N N N N N N N |
|-----|--|
| 383 | Br N N N N N N N N N N N N N N N N N N N |
| 384 | |
| 385 | |

| 386 | |
|-----|--|
| 387 | |
| 388 | |
| 389 | |

| 390 | |
|-----|----------|
| 391 | CI N H H |
| 392 | |
| 393 | |

| 394 | CI N N N N N N N N N N N N N N N N N N N |
|------|--|
| 2001 | ON N N S N S N S N S N S N S N S N S N S |
| 2002 | O O N S N N N N N N N N N N N N N N N N |
| 2003 | O O O O O O O O O O O O O O O O O O O |
| 2004 | O O O N S N O O O O O O O O O O O O O O |
| 2005 | OH NMe ₂ |

| 2006 | ON NO N |
|------|--|
| | F ₃ C N N O |
| | O≕(OH NMe ₂ |
| 2007 | O O N S N |
| | |
| | O⇒OH NMe ₂ |
| 2008 | NS N |
| | NH NH NH |
| | OH MeO NMe2 |
| 2009 | ON S N |
| | OMe H H |
| | O OH NMe ₂ |
| 2010 | 0,0 N,S,N |
| | |
| | O=OH NMe ₂ |
| 2011 | NS N |
| | N N N |
| | O—OH NMe ₂ OMe |
| 2012 | ON ON NO N |
| | |
| | OH NMe ₂ |
| | OMe |

| 2013 | F ₃ C N N N N N N N N N N N N N N N N N N N |
|------|--|
| 2014 | NMe ₂ OSO N N N N N N N N N N N N N N N N N |
| 2015 | O OH NMe ₂ |
| 2016 | O O O O O O O O O O O O O O O O O O O |
| 2017 | ON N N N N N N N N N N N N N N N N N N |
| 2018 | O O O O O O O O O O |
| 2019 | ON NH |

| 2020 | ON O |
|------|--|
| 2021 | |
| 2022 | O O N N HN O O O O O O O O O O O O O O O |
| 2023 | O O O N N N O OMe OMe |
| 2024 | O O O N N N N N N N N N N N N N N N N N |
| 2025 | O N N H O O Me |
| 2026 | O O O O O O O O O O O O O O O O O O O |

| 2027 | O O N N N N N N N N N N N N N N N N N N |
|------|---|
| 2028 | ON NON HN |
| 2029 | N N HN |
| 2031 | ON HN HN ON |
| 2032 | N S O OH H N N N N N N N N N N N N N N N N |
| 2033 | N S O OH H |
| 2034 | O O O N O O O O O O O O O O O O O O O O |

| 2035 | |
|------|---|
| | O S O O O O O O O O O O O O O O O O O O |
| 2036 | 0,0 |
| | N S O OH H H |
| 2037 | 0,0 |
| | |
| | OO OH H H |
| 2038 | 0,0 |
| | |
| | OH H H |
| 2039 | Q, 0 N, S, 1 |
| | Br N N |
| | OH H H |
| 2040 | O O O |
| | N N N N N N N N N N N N N N N N N N N |
| | о он н н (|
| 2041 | 0,0 |
| | N N N N N N N N N N N N N N N N N N N |
| | OSO OH N N |
| 2042 | N N N |
| | |
| | о он н н г |

| 2043 | O O O O O O O O O O O O O O O O O O O |
|------|--|
| 2044 | N S O OH H H |
| 2045 | |
| 2046 | ON NHN HN |
| 2047 | Br N HN O |
| 2049 | OH HN TO |
| 2050 | O, O N, S, N |

| 2051 | 0, 0 |
|------|----------|
| 2031 | N.S.N. Y |
| | |
| | O H H |
| | N OH |
| | OH_OH_ |
| 2052 | 0,0 |
| | N V |
| | N HN TO |
| | N OH |
| | |
| | N |
| 2053 | 0, o |
| | Br N N |
| | N HN O |
| | N OH |
| 2054 | Q, o |
| | NON Y |
| | N HN |
| | N OH |
| | . С |
| 2055 | 0,0 |
| | N N V |
| | N HN O |
| | N OH |
| į | ОН |
| 2056 | 0,0 |
| | NON V |
| | O H H O |
| 1 | N OH |
| | ОН |

| 2057 | Br OH N N OH OH |
|------|---|
| 2058 | OH N N N |
| 2059 | ON NHN HN |
| 2060 | |
| 2062 | |
| 2063 | O N N N N N N N N N N N N N N N N N N N |

| 2064 | ON N HN |
|------|--|
| 2065 | |
| 2066 | |
| 2067 | N H ₃ C CH ₃ CH ₃ |
| 2068 | N S N N N N N N N N N N N N N N N N N N |

| 2069 | N S N N N N N N N N N N N N N N N N N N |
|------|--|
| 2070 | N S N N N N N N N N N N N N N N N N N N |
| 2071 | O O O N S N S N O O O O O O O O O O O O |
| 2072 | |
| 2073 | O O O O O O O O O O O O O O O O O O O |
| 2074 | O O O O O O O O O O O O O O O O O O O |
| 2075 | O, O N, S, N, |

| 2076 | 0. 0 |
|------|---|
| 2076 | N,S,N |
| | NS N |
| | N N |
| | N OH H H |
| | OH PO |
| | |
| 2077 | O, ,O ,S, |
| | N N |
| | |
| | |
| | N- OH H H |
| | O |
| 2078 | O, O |
| | N, N |
| | |
| | \ \ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ |
| | N- OH H H |
| 2079 | 0,0 |
| | N. N. |
| | |
| | N N N |
| | N-OH H H |
| 2080 | |
| 2080 | N N Y |
| | |
| | / (|
| | N H H I N |
| | OH OH |
| | |

| 2081 | 0,0 |
|------|---------------------|
| | N.S.N |
| | |
| | N H H |
| | N OH () |
| 2000 | 0 0 |
| 2082 | NS N |
| | NS N D |
| | H H |
| | N-OH H H |
| | |
| 2083 | |
| | N N |
| | N N N |
| | , N- (OH " " (_) F |
| 2084 | 0,0 |
| | NS N |
| | $N \sim N$ |
| | OH H H |
| | |
| 2085 | 0, 0 |
| 2000 | O, O N,S, N |
| | |
| | N H H |
| |), OH ()~o |
| | 0 F |

| 2086 | 0,,0 |
|------|--------------------|
| | |
| | N H H |
| | N OH OH |
| 2087 | ON SIN |
| | |
| | N OH H H |
| | F F |
| 2088 | 0, 0 N, S, N |
| | N,S,N |
| | OH H H |
| 2089 | O, O N, S, N \/ |
| | |
| | N OH H H |
| | 0 0- |
| 2090 | |
| | N.S.N Y |
| | N N N |
| | OH S—>O |
| | ١ |

| 2091 | |
|----------|--------------------|
| | |
| | |
| | N N |
| | N H H H |
| | |
| | |
| 2092 | 0, 0 |
| | 0, 0 N, N |
| | NSN Y |
| | |
| | |
| i | OH CI |
| • | |
| 0000 | Cl |
| 2093 | O, O N, S, N \/ |
| | NON V |
| | |
| | |
| | N-OH H H |
| | ' Ö |
| 0004 | 0.0 |
| 2094 | N.S.N. |
| | |
| | |
| | |
| | N-(OH H H |
| | |
| | 0 0 |
| 2095 | N.S.N. |
| | |
| | |
| | N N |
| | N- OH H H |
| | ' "o " |
| | j → 6 |
| <u> </u> | |

| 2096 | ON NO N |
|------|--|
| 2097 | Br NSN N N N N N N N N N N N N N N N N N |
| 2098 | ON ON NO NO H H H |
| 2099 | ON ON NO N |
| 2100 | ON ON NO N |

| 2101 | 0, 0 |
|------|---|
| 2101 | N N |
| | |
| | Br—NNN |
| | N H H |
| | OH OH |
| 2102 | O. O. |
| | N.S.N |
| | |
| | N-S OH H H |
| | O OH |
| 0100 | 0 0 |
| 2103 | O, O N S N \ |
| | |
| | Br-N N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N- |
| | N- OH H H |
| | |
| 2104 | 0,,0 |
| | 0, 0 N, N |
| | |
| | H H |
| | OH (_)^O _ |
| | 01 |
| 2105 | 0,,0 |
| | N.S.N |
| | |
| | \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ |
| | OH OH |
| | · |

| 0100 | 0. 0 |
|------|--------------------|
| 2106 | |
| | N ^S N V |
| | N = N = N |
| | |
| | N- OH H H |
| 2107 | O'S'LO |
| | N, S,N \ F |
| | |
| | N N |
| | N- OH " I |
| 2108 | 0,,0 |
| | N F F |
| | |
| | N N |
| | N OH H H |
| | / 0 011 |
| 2109 | O, O N, S, N |
| | N N |
| | |
| | HH |
| | N OH H H |
| 2110 | 0 |
| 2110 | 0,0 |
| | N, S, N |
| | |
| | N N |
| | N- |
| | |
| | \/ \ |
| | |

| 0111 | 0.0 |
|------|----------------|
| 2111 | |
| | N. N. V |
| | N.S.N |
| | |
| | |
| | N- OH H H |
| | $ ' \circ $ |
| | N- |
| | /\ |
| 2112 | 0,,,0 |
| | N.S.N \/ |
| | |
| | |
| | |
| | N OH H H |
| | NA OH () |
| | |
| | and |
| 2113 | \circ |
| 2113 | N.S.N. |
| | |
| | |
| | , /_ , N N N |
| | N-OH H H |
| | OH () |
| | |
| | 0 . |